Beth Hoffman

Company: Origami Therapeutics, Inc.

Job title: Founder & Chief Executive Officer

Seminars:

4.00 Optimizing Protein Degraders for Neurodegeneration 9:30 am

Considerations for optimizing the best leads Use of patient iPSC-derived neurons as a translational model Demonstration of PK/PD relationships in preclinical rodent modelsRead more

day: Day One Track B PM